Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000469271 | SCV000547682 | likely benign | Primary ciliary dyskinesia | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001333455 | SCV001526031 | uncertain significance | Primary ciliary dyskinesia 24 | 2018-05-11 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Genetics and Molecular Pathology, |
RCV000469271 | SCV002761794 | uncertain significance | Primary ciliary dyskinesia | 2019-10-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002526411 | SCV003760800 | uncertain significance | Inborn genetic diseases | 2022-01-27 | criteria provided, single submitter | clinical testing | The c.907A>G (p.R303G) alteration is located in exon 9 (coding exon 9) of the RSPH1 gene. This alteration results from a A to G substitution at nucleotide position 907, causing the arginine (R) at amino acid position 303 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004755921 | SCV005354762 | likely benign | RSPH1-related disorder | 2024-04-18 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |